Sanofi: presents results for Praluent
(CercleFinance.com) - Sanofi announces that the results of new analyses of mortality in the Odyssey outcomes clinical trial, which included 18,924 patients, have been presented at the 2018 scientific sessions of the American Heart Association (AHA).
As part of this trial, Praluent administered as a supplement to statins at the maximum tolerated dose was compared with statin therapy at the maximum tolerated dose only in patients who had presented an SCA over the previous 12 months.
The data published in the New England Journal of Medicine last week already showed that Praluent had significantly reduced the risk of major cardiovascular events and that it was associated with a reduced risk of mortality of all causes combined.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
As part of this trial, Praluent administered as a supplement to statins at the maximum tolerated dose was compared with statin therapy at the maximum tolerated dose only in patients who had presented an SCA over the previous 12 months.
The data published in the New England Journal of Medicine last week already showed that Praluent had significantly reduced the risk of major cardiovascular events and that it was associated with a reduced risk of mortality of all causes combined.
Copyright (c) 2018 CercleFinance.com. All rights reserved.